Бронхолитическая терапия хронической обструктивной болезни легких стабильного течения

1. Global initiative for chronic obstructive lung disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI / WHO workshop report. National Heart, Lung, and Blood Institute 2001; publ. number 2701.

2. Loddenkemper R, Gibson G.J. et al. European lung white book. The first comprehensive survey on respiratory health in Europe. London; 2003. 34–43.

3. Mahler D.A., Donohue J.F., Barbee R.A. et al. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest 1999; 115 (4): 957–965.

4. Cеlli B.R., MacNee W. and committee members. Standards for diagnosis and treatment of patients with COPD: a summary of ATS / ERS position paper. Eur. Respir. J. 2004; 23 (6): 932–946.

5. Global initiative for chronic obstructive lung disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI / WHO workshop report. National Heart, Lung, and Blood Institute, update 2004. www.goldcopd.com.

6. Чучалин А.Г. (ред.) Хроническая обструктивная болезнь легких. Федеральная программа. (Издание 2-е, переработанное и дополненное). М.; 2004.

7. Wright J.L., Levy R.D., Churg A. Pulmonary hypertension in chronic obstructive pulmonary disease: current theories of pathogenesis and their implication for treatment. Thorax 2005; 60: 605–609.

8. Anderson G.P., Linden A., Rabe K.F. Why are long-acting beta-adrenoceptor agonists long acting? Eur. Respir. J. 1994; 7 (3): 569–578.

9. Cazzola M., Santagello G., Piccolo A. et al. Effect of salmeterol and formoterol in patients with chronic obstructive pulmonary disease // Pulm Pharmacol. –1994.– Vol 7. – P. 103–107

10. Celic G., Kayacan O., Beder S. et al. Formoterol and salmeterol in partially reversible chronic obstructive pulmonary disease: a crossover, placebo controlled comparison of onset and duration of action. Respiration 1999; 66: 434–439.

11. Barnes P. Theoretical aspects of anticholinergic treatment. In: Anticholinergic therapy in obstructive airways disease / Gross N., ed. London: Franklin Scientific Publications; 1993. 88–104.

12. Gross N.J. Tiotropium bromide. Chest 2004; 126 (6): 1946–1953.

13. Barnes P. Theophylline. New perspective for an old drug. Am. J. Respir. Crit. Care Med. 2003; 167 (6): 813–818.

14. Sutherland E.R., Cherniak R.M. Management of chronic obstructive pulmonary disease. N. Engl. J. Med. 2004; 350 (26): 2689–2697.

15. Barnes P. Management of chronic obstructive pulmonary disease. Science Press Ltd; 1999. 35–40.

16. Chronic obstructive pulmonary disease. National clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care. Thorax 2004; 59 (suppl. 1): 1–232.

17. Husereau D., Shukla V., Boucher M. et al. Long acting β2-agonists for stable chronic obstructive pulmonary disease with poor reversibility: a systematic review of randomized controlled trials. BMC Pulm. Med. 2004; 4: 7–18.

18. Rennard S.I., Anderson W, Zuwallack R et al. Use of long acting inhaled β2-adrenerergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2001; 163 (5): 1087–1092.

19. Stahl E., Wadbo M., Bengtsson T. et al. Health-related quality of life, symptoms, exercise capacity and lung function during treatment for moderate to severe COPD. J. Drug Assess. 2002; 5: 81–94.

20. van Noord J.A., de Munck D.R., Banje T.A. et al. Long term treatment of chronic obstructive pulmonary disease with salmeterol and additive effect of iptaropium. Eur. Respir. J. 2000; 15 (5): 878–885.

21. Burge P.S. EUROSCOP, ISOLDE and the Copenhagen City Lung Study. Thorax 1999; 54 (4): 287–288.

22. Burge P.S., Calverley P.M.A., Jones P.W. et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. Br. Med. J. 2000; 320 (7245): 1297–1303.

23. Pauwels R.A., Lofdahl C)G., Laitinen L.A. et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. N. Engl. J. Med. 1999; 340 (25): 1948–1953.

24. The Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease // N. Eng. J. Med.– 2000.– Vol. 343, N 26.– P. 1902–1909.

25. Vestbo J., Sorensen T., Lange P. et al. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease. Lancet. 1999; 353 (9167): 1819–1823.

26. Alsaeedi A., Sin D.D., McAlister F.A. The effect of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review of randomized placebo-controlled trials. Am. J. Med. 2002; 113 (1): 56–65.

27. Culpitt S.V., Nighthingale J.A., Barnes P. Effect of fluticasone propionate on induced sputum matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with COPD. Am. Rev. Respir. Crit. Care Med. 1999; 160 (5, pt 1): 1635–1639.

28. Keatings V.M., Jatakanon A., Worsdel Y.)M., Barnes P. Effect of inhaled and oral glucocorticoids on infalammatory indices in asthma and COPD. Am. Rev. Respir. Crit. Care Med. 1997; 155 (2): 542–548.

29. Barnes P.J., Adcock I. M, Ito K. Histone diacetylation and deacetylation importance in inflammatory lung diseases. Eur. Respir. J. 2005; 25 (3): 552–563.

30. Ito K., Lim S., Caramori G. et al. Cigarette smoking reduces histone deacetylase 2 expression, enhances cytokine expression and inhibits glucocorticoid actions in alveolar macrophages. FASEB J. 2001; 15 (6): 1100–1102.

31. Calverley P., Pauwels R., Vestbo J. et al. Combined salmeterol and fluticason in the treatment of chronic obstructive pulmonary disease: a randomized controlled trial. Lancet 2003; 361 (9356) 449–456

32. Calverley P., Boonswat W., Cseke Z. et al. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur. Respir. J. 2003; 22 (6): 912–919.

33. Mahler D.A., Wire P., Horstman D. et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the Discus device in the treatment of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2002; 166: 1084–1091.

34. Szafranski W, Cukier A, Ramiez A. et al. Efficacy and safety of budesonide / formoterol in the management of chronic obstructive pulmonary disease. Eur. Respir. J. 2003; 21 (1): 74–81.

35. Wouter E.F.M., Postma D., Fokkens B. et al. Withdrawal of fluticasone propionate from combined salmeterol / fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomized controlled trial. Thorax 2005; 60: 480–487.

36. Anzueto A., Tashkin D., Menjoge S., Kesten S. One year analysis of longitudinal changes in spirometry in patents with COPD receiving tiotropium. Pulm. Pharm. Ther. 2005; 18: 75–81.

37. Brusasco V., Hodder R., Miravitlles M. et al. Health outcomes following treatment for six months with one daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax 2003; 58: 399–404.

38. Casaburi R, Mahler DA, Johnes PW et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur. Respir. J. 2002; 19 (2): 217–224.

39. Donohue J.F., Menjorge E., Kesten S. Tolerance to bronchodulating effect of salmeterol on COPD. Respir. Med. 2003; 97: 1014–1020.

40. Vincken W., van Noord A.P.M., Greefrost Th.A et. al. Improvement health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur. Respir. J. 2002; 19 (2): 209–216.

41. Celli B., ZuWallack R., Wang S, Kesten S. Improvement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumes. Chest 2003; 124: 1743–1748.

42. O'Donnel D.E., Fluge T., Gerken F. et al. Effect of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur. Respir. J. 2004; 23 (6): 832–840.

43. van Noord J.A., Smeets J.J., Custers F.L.J. et al. Pharmacodynamic steady state of tiotropium in patients with chronic obstructive pulmonary disease. Eur. Respir. J. 2002; 19 (4): 639–644.

44. Casaburi R., Kukafka D., Cooper C.B. et al. Improvement in exercise tolerance with the combination of Thiotropium and pulmonary rehabilitation in patients with COPD. Chest 2005; 127 (3): 809–817.

45. van Noord J.A., Bantie Th.A., Eland M.E. et al. A randomized controlled comparison of tiotropium and ipratropium in the treatment of COPD. Thorax 2000; 55 (4): 289–294.

46. Briggs D.D., Covelli H., Lapidius R. et al. Improvement daytime spirometric efficacy of tiotropium compared with salmeterol in patients with COPD. Pulm. Pharm. Ther. 2005; 18 (6): 397–404.

47. Donohue J.F., van Nord J.A., Bateman E.D. et al. A 6-months, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 2002; 122 (1): 47–55

48. van Noord J.A., Aumann J.L., Janssens E. et al. Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. Eur. Respir. J. 2005; 26 (2): 214–222.

49. Cazzola M, Imperatore F, Salzillo A. et al. Cardiac effect of formoterol and salmeterol in patients suffering from COPD with preexisting cardiac arrhythmias and hypoxemia. Chest 1998; 114 (2): 411–415.

50. Cooper C.B., Tashkin D.P. Recent developments in inhaled therapy in stable chronic obstructive pulmonary disease. Br. Med. J. 2005; 330: 640–644.

51. Currie G.P., Rossiter C., Miles S.A. et al. Effects of tiotropium and other long acting bronchodilators in chronic obstructive pulmonary disease. Pulm. Pharm. Ther. 2005; E. publication June 18.